| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2717693 | The American Journal of Medicine | 2006 | 8 Pages |
Abstract
Despite the well-established benefits of available lipid-modifying drugs, current management of dyslipidemia continues to be suboptimal, with a substantial proportion of patients failing to achieve guideline-recommended lipid targets. There remains an important opportunity to improve the quality of care for these high-risk patients.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Andrew T. MD, Raymond T. MD, Mary BSc, Daniel G. MD, Kori L. BScPhm, Heather PharmD, Jennifer L. MD, Shahin MD, MHSc, Martin L. MD, Lawrence A. MD, David H. MD, Anatoly MD, MSc, Shaun G. MD, MSc,